Double Whammy For ALS As AbbVie/Calico And Denali Drugs Fail

Two treatments that target elF2B, a regulator of the integrated stress response that appears to be overactive in the progressive motor neurone disease, have missed their primary and secondary endpoints in a landmark platform trial.